Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Detalles Bibliográficos
Autores principales: Sharman, Jeff P., Egyed, Miklos, Jurczak, Wojciech, Skarbnik, Alan, Pagel, John M., Flinn, Ian W., Kamdar, Manali, Munir, Talha, Walewska, Renata, Corbett, Gillian, Fogliatto, Laura Maria, Herishanu, Yair, Banerji, Versha, Coutre, Steven, Follows, George, Walker, Patricia, Karlsson, Karin, Ghia, Paolo, Janssens, Ann, Cymbalista, Florence, Woyach, Jennifer A., Ferrant, Emmanuelle, Wierda, William G., Munugalavadla, Veerendra, Yu, Ting, Wang, Min Hui, Byrd, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979808/
https://www.ncbi.nlm.nih.gov/pubmed/34974526
http://dx.doi.org/10.1038/s41375-021-01485-x

Ejemplares similares

Ejemplares similares